Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioCellChallenge Launches the First Universal Delivery System

Published: Thursday, February 21, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
This new technology means thousands of existing antibodies can now be used as research tools, with or without additives.

BioCellChallenge SAS has announced the launch of a new delivery system, ImmunoCellin, which is designed to transport antibodies into live cells even in the presence of additives. The company has recently filed a patent for this pioneering technology.

Without a suitable nanocarrier, antibodies cannot cross the plasmic membrane of live cells unaided and reach their potential intracellular targets.

ImmunoCellin delivers antibodies directly into live cells, without any particular advanced preparation. This system is especially effective in identifying new targets for future therapeutic treatments.

"Until now, cellular biology research projects have made little use of antibody transport into live cells, largely because all the tools are not sufficiently effective to be used without a lot of preparation or re-engineering. However, there is particular benefit in introducing therapeutic antibodies to target the intracellular proteins involved in certain diseases, particularly in certain cancers," explains Dr Meunier, CEO of BioCellChallenge.

ImmunoCellin is a much more potent protein function inhibitor than siRNA (small interfering RNA). Using siRNA to prevent a protein from playing its role in the cell inhibits all the functions of that protein.

With ImmunoCellin, however, monoclonal antibodies can be directed to a single region of the protein to interfere with a single molecular mechanism, meaning that a specific function of the protein can be determined with certainty.

ImmunoCellin is therefore a powerful tool for developing a broader understanding of the inter-protein interactions which form the basis of cell function.

ImmunoCellin is also particularly suitable for use in kinetic studies of intracellular protein localization in response to different stimuli. It can also directly interfere with protein traffic in the cytosol or the nucleus; by targeting a localization signal, for example.

The reagent is very simple to use: a few microlitres of the reagent are mixed with a few micrograms of antibody and this mixture is then added to the cells.

No other preparation is required. The lipid-based formulation encapsulates the antibodies, facilitating their passage through the membrane.

There is no covalent interaction between the transport system and the antibody. Once inside the cell, the system does not retain the antibody, which can then diffuse freely through the cytosol until it reaches its target.

Since no chemical coupling is required, there is no impact on the activity of the antibody. Finally, as this system is not inhibited by the presence of serum, in vivo approaches are also possible.

This new system is aimed particularly at pharmaceutical and biotechnology industry R&D teams working on therapeutic antibodies.

Accordingly, BioCellChallenge is keen to develop partnerships with players in the pharmaceutical and biotechnology industry. The ImmunoCellin system is also particularly relevant to cellular and molecular research biologists worldwide.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!